Novartis receives FDA accelerated approval for Fabhalta® (iptacopan)
- Details
- Category: Novartis

Vividion Therapeutics to expand with new global research and development center
- Details
- Category: Bayer

Pfizer announces positive topline results From Phase 3 study of hemophilia A gene therapy candidate
- Details
- Category: Pfizer

The AFFINE study achieved its primary objective of non-inferiority, as well as superiority, of total annualized bleeding rate (ABR) from Week 12 through at least 15 months of follow up post-infusion compared with routine Factor VIII (FVIII) replacement prophylaxis treatment.
Darolutamide meets primary endpoint in Phase III ARANOTE trial
- Details
- Category: Bayer

Pfizer advances development of once-daily formulation of oral GLP-1 receptor agonist danuglipron
- Details
- Category: Pfizer

AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease
- Details
- Category: Bayer

GSK and CureVac to restructure collaboration into new licensing agreement
- Details
- Category: GlaxoSmithKline

Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases.
More Pharma News ...
- Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention
- Berlin Center for Gene and Cell Therapies kicked off in Berlin
- Bayer receives Breakthrough Therapy designation in China for BAY 2927088
- GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies
- Pfizer's LORBRENA® CROWN study shows majority of patients with ALK-positive advanced lung cancer living beyond five years without disease progression
- BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel
- Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration